Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma

S. Lonial, M. Dimopoulos, A. Palumbo, D. White, S. Grosicki, I. Spicka, A. Walter-Croneck, P. Moreau, MV. Mateos, H. Magen, A. Belch, D. Reece, M. Beksac, A. Spencer, H. Oakervee, RZ. Orlowski, M. Taniwaki, C. Röllig, H. Einsele, KL. Wu, A....

. 2015 ; 373 (7) : 621-31. [pub] 20150602

Language English Country United States

Document type Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc15031330
E-resources Online Full text

NLK ProQuest Central from 1980-01-03 to 3 months ago
Nursing & Allied Health Database (ProQuest) from 1980-01-03 to 3 months ago
Health & Medicine (ProQuest) from 1980-01-03 to 3 months ago
Family Health Database (ProQuest) from 1980-01-03 to 3 months ago
Psychology Database (ProQuest) from 1980-01-03 to 3 months ago
Health Management Database (ProQuest) from 1980-01-03 to 3 months ago
Public Health Database (ProQuest) from 1980-01-03 to 3 months ago

Links

PubMed 26035255
DOI 10.1056/nejmoa1505654
Knihovny.cz E-resources

BACKGROUND: Elotuzumab, an immunostimulatory monoclonal antibody targeting signaling lymphocytic activation molecule F7 (SLAMF7), showed activity in combination with lenalidomide and dexamethasone in a phase 1b-2 study in patients with relapsed or refractory multiple myeloma. METHODS: In this phase 3 study, we randomly assigned patients to receive either elotuzumab plus lenalidomide and dexamethasone (elotuzumab group) or lenalidomide and dexamethasone alone (control group). Coprimary end points were progression-free survival and the overall response rate. Final results for the coprimary end points are reported on the basis of a planned interim analysis of progression-free survival. RESULTS: Overall, 321 patients were assigned to the elotuzumab group and 325 to the control group. After a median follow-up of 24.5 months, the rate of progression-free survival at 1 year in the elotuzumab group was 68%, as compared with 57% in the control group; at 2 years, the rates were 41% and 27%, respectively. Median progression-free survival in the elotuzumab group was 19.4 months, versus 14.9 months in the control group (hazard ratio for progression or death in the elotuzumab group, 0.70; 95% confidence interval, 0.57 to 0.85; P<0.001). The overall response rate in the elotuzumab group was 79%, versus 66% in the control group (P<0.001). Common grade 3 or 4 adverse events in the two groups were lymphocytopenia, neutropenia, fatigue, and pneumonia. Infusion reactions occurred in 33 patients (10%) in the elotuzumab group and were grade 1 or 2 in 29 patients. CONCLUSIONS: Patients with relapsed or refractory multiple myeloma who received a combination of elotuzumab, lenalidomide, and dexamethasone had a significant relative reduction of 30% in the risk of disease progression or death. (Funded by Bristol-Myers Squibb and AbbVie Biotherapeutics; ELOQUENT-2 ClinicalTrials.gov number, NCT01239797.).

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc15031330
003      
CZ-PrNML
005      
20151014130230.0
007      
ta
008      
151005s2015 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1056/NEJMoa1505654 $2 doi
035    __
$a (PubMed)26035255
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Lonial, Sagar $u From Winship Cancer Institute, Emory University School of Medicine, Atlanta (S.L.); National and Kapodistrian University of Athens, Athens (M.D.); A.O.U. San Giovanni Battista di Torino-Ospedale Molinette, Turin, Italy (A.P.); QEII Health Science Center and Dalhousie University, Halifax, NS (D.W.), Cross Cancer Institute and University of Alberta, Edmonton (A.B.), and Princess Margaret Cancer Centre, Toronto (D.R.) - all in Canada; Silesian Medical University, Katowice (S.G.), and Medical University of Lublin, Lublin (A.W.-C.) - both in Poland; Charles University Hospital, Prague, Czech Republic (I.S.); University Hospital, Nantes, France (P.M.); Complejo Asistencial Universitario de Salamanca-Instituto de Investigación Biomédica de Salamanca, Salamanca (M.-V.M.), and Clinica Universidad de Navarra-Centro de Investigación Médica Aplicada, Instituto de Investigación Sanitaria de Navarra, Pamplona (J.S.-M.) - both in Spain; Davidoff Cancer Center, Rabin Medical Center, Petah Tikva, and Tel Aviv University, Ramat Aviv - both in Israel (H.M.); Ankara University, Ankara, Turkey (M.B.); Alfred Health-Monash University, Melbourne, VIC, Australia (A. Spencer); Barts and the London NHS Trust, London (H.O.); University of Texas M.D. Anderson Cancer Center, Houston (R.Z.O.); Kyoto Prefectural University of Medicine, Kyoto (M.T.), and Nishigunma National Hospital, Shibukawa (M.M.) - both in Japan; Universitätsklinikum der Technische Universität, Dresden (C.R.), and Universitätsklinikum Würzburg, Würzburg (H.E.) - both in Germany; Zeikenhuis Netwerk Antwerpen (ZNA) Stuivenberg, Antwerp, Belgium (K.L.W.); AbbVie Biotherapeutics, Redwood City, CA (A. Singhal); Bristol-Myers Squibb, Princeton, NJ (J.K.), Wallingford, CT (E.B.), and Braine-l'Alleud, Belgium (V.P.); and Dana-Farber Cancer Institute, Boston (K.C.A., P.R.).
245    10
$a Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma / $c S. Lonial, M. Dimopoulos, A. Palumbo, D. White, S. Grosicki, I. Spicka, A. Walter-Croneck, P. Moreau, MV. Mateos, H. Magen, A. Belch, D. Reece, M. Beksac, A. Spencer, H. Oakervee, RZ. Orlowski, M. Taniwaki, C. Röllig, H. Einsele, KL. Wu, A. Singhal, J. San-Miguel, M. Matsumoto, J. Katz, E. Bleickardt, V. Poulart, KC. Anderson, P. Richardson, . ,
520    9_
$a BACKGROUND: Elotuzumab, an immunostimulatory monoclonal antibody targeting signaling lymphocytic activation molecule F7 (SLAMF7), showed activity in combination with lenalidomide and dexamethasone in a phase 1b-2 study in patients with relapsed or refractory multiple myeloma. METHODS: In this phase 3 study, we randomly assigned patients to receive either elotuzumab plus lenalidomide and dexamethasone (elotuzumab group) or lenalidomide and dexamethasone alone (control group). Coprimary end points were progression-free survival and the overall response rate. Final results for the coprimary end points are reported on the basis of a planned interim analysis of progression-free survival. RESULTS: Overall, 321 patients were assigned to the elotuzumab group and 325 to the control group. After a median follow-up of 24.5 months, the rate of progression-free survival at 1 year in the elotuzumab group was 68%, as compared with 57% in the control group; at 2 years, the rates were 41% and 27%, respectively. Median progression-free survival in the elotuzumab group was 19.4 months, versus 14.9 months in the control group (hazard ratio for progression or death in the elotuzumab group, 0.70; 95% confidence interval, 0.57 to 0.85; P<0.001). The overall response rate in the elotuzumab group was 79%, versus 66% in the control group (P<0.001). Common grade 3 or 4 adverse events in the two groups were lymphocytopenia, neutropenia, fatigue, and pneumonia. Infusion reactions occurred in 33 patients (10%) in the elotuzumab group and were grade 1 or 2 in 29 patients. CONCLUSIONS: Patients with relapsed or refractory multiple myeloma who received a combination of elotuzumab, lenalidomide, and dexamethasone had a significant relative reduction of 30% in the risk of disease progression or death. (Funded by Bristol-Myers Squibb and AbbVie Biotherapeutics; ELOQUENT-2 ClinicalTrials.gov number, NCT01239797.).
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a humanizované monoklonální protilátky $x škodlivé účinky $x terapeutické užití $7 D061067
650    _2
$a protokoly protinádorové kombinované chemoterapie $x škodlivé účinky $x terapeutické užití $7 D000971
650    _2
$a dexamethason $x terapeutické užití $7 D003907
650    _2
$a přežití bez známek nemoci $7 D018572
650    _2
$a lidé $7 D006801
650    _2
$a lidé středního věku $7 D008875
650    _2
$a mnohočetný myelom $x farmakoterapie $x mortalita $7 D009101
650    _2
$a receptory imunologické $x antagonisté a inhibitory $7 D011971
650    _2
$a recidiva $7 D012008
650    _2
$a thalidomid $x analogy a deriváty $x terapeutické užití $7 D013792
655    _2
$a klinické zkoušky, fáze III $7 D017428
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Dimopoulos, Meletios
700    1_
$a Palumbo, Antonio
700    1_
$a White, Darrell
700    1_
$a Grosicki, Sebastian
700    1_
$a Spicka, Ivan
700    1_
$a Walter-Croneck, Adam
700    1_
$a Moreau, Philippe
700    1_
$a Mateos, Maria-Victoria
700    1_
$a Magen, Hila
700    1_
$a Belch, Andrew
700    1_
$a Reece, Donna
700    1_
$a Beksac, Meral
700    1_
$a Spencer, Andrew
700    1_
$a Oakervee, Heather
700    1_
$a Orlowski, Robert Z
700    1_
$a Taniwaki, Masafumi
700    1_
$a Röllig, Christoph
700    1_
$a Einsele, Hermann
700    1_
$a Wu, Ka Lung
700    1_
$a Singhal, Anil
700    1_
$a San-Miguel, Jesus
700    1_
$a Matsumoto, Morio
700    1_
$a Katz, Jessica
700    1_
$a Bleickardt, Eric
700    1_
$a Poulart, Valerie
700    1_
$a Anderson, Kenneth C $7 gn_A_00006159
700    1_
$a Richardson, Paul
700    1_
$a ,
773    0_
$w MED00003517 $t The New England journal of medicine $x 1533-4406 $g Roč. 373, č. 7 (2015), s. 621-31
856    41
$u https://pubmed.ncbi.nlm.nih.gov/26035255 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20151005 $b ABA008
991    __
$a 20151014130420 $b ABA008
999    __
$a ok $b bmc $g 1092206 $s 914456
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2015 $b 373 $c 7 $d 621-31 $e 20150602 $i 1533-4406 $m The New England journal of medicine $n N Engl J Med $x MED00003517
LZP    __
$a Pubmed-20151005

Find record

Citation metrics

Archiving options